RecruitingNot ApplicableNCT05424159

Ablative Carbon Ion Radiotherapy With Pencil Beam Scanning for Locally Advanced Unresectable Pancreatic Cancer

Prospective Phase II Clinical Trial of Ablative Carbon Ion Radiotherapy With Pencil Beam Scanning Using Simultaneous Integrated Boost for Locally Advanced Unresectable Pancreatic Cancer


Sponsor

Shanghai Proton and Heavy Ion Center

Enrollment

48 participants

Start Date

Jul 1, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

The aim of this study is to investigate the clinical efficacy and safety of ablative carbon ion radiotherapy for locally advanced unresectable pancreatic cancer with pencil beam scanning and simultaneous integrated boost (SIB) technology.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a highly precise form of radiation therapy called carbon ion radiotherapy for people with locally advanced pancreatic cancer that cannot be surgically removed. Carbon ion beams can target tumors more precisely than conventional radiation, potentially causing less damage to nearby organs. **You may be eligible if:** - You are at least 18 years old - You have pancreatic cancer confirmed by biopsy (ductal adenocarcinoma) - Your cancer has not spread to distant organs but cannot be surgically removed (Stage III) - Your tumor is 7 cm or smaller - The tumor has not grown into your stomach, duodenum, or small intestine - You are in reasonably good health (ECOG 0–1) - Your blood counts, liver, and kidney function are within acceptable ranges **You may NOT be eligible if:** - You have multiple tumors in the pancreas - The tumor has invaded the digestive tract directly - You have had prior radiation therapy or other local treatments for pancreatic cancer - You have had another cancer previously - You cannot understand or consent to the treatment Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATIONCarbon ion radiotherapy

Patients with locally advanced unresectable pancreatic cancer without invasion of gastrointestinal tract will received ablative carbon ion radiotherapy. The prescription dose for primary pancreatic lesion, positive lymph node, and retroperitoneal high-risk recurrence area is 67.5 Gy (RBE weighted dose) in 15 fractions for 3 weeks; Pancreatic primary lesion and positive lymph node SIB to 75 Gy (RBE weighted dose) in 15 fractions for 3 weeks.


Locations(1)

Shanghai Proton and Heavy Ion Center

Shanghai, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05424159


Related Trials